RegulatoryCompany release

FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC

🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026

The agency found HARMONi's progression-free survival gain, without a significant overall survival improvement, did not show substantial evidence of effectiveness or a positive benefit-risk profile.

Summit Therapeutics said on 15 November 2026 that the US Food and Drug Administration has issued a Complete Response Letter for its Biologics License Application for ivonescimab. The product was proposed in combination with platinum chemotherapy for locally advanced or metastatic non-small cell lung cancer after prior treatment with an EGFR tyrosine kinase inhibitor.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Summit Therapeutics Inc. ↗

Article written by VigiEye from the official source (Summit Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →